A Trial of SHR-1703 in Healthy Subjects

Summary

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.

Timeline

Start

2021-06-14

Primary completion

2021-09-13

Completion

2021-11-18

Outcome

Outcome not reported

Stopped: “Adjustment of the clinical development plan for this product globally”

Drugs

Indications